FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1828400840> ?p ?o ?g. }

• W1828400840 endingPage "1202" @default.
• W1828400840 startingPage "1193" @default.
• W1828400840 abstract "// Qing-Chun Huang 1 , Mao-Jie Wang 2 , Xiu-Min Chen 1 , Wan-Lin Yu 2 , Yong-Liang Chu 1 , Xiao-Hong He 1 and Run-Yue Huang 1 1 Department of Rheumatology, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China 2 Central Laboratory, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China Correspondence to: Run-Yue Huang, email: // Keywords : licorice, glycyrrhizin, glycyrrhetinic acid, rheumatoid arthritis, the COX-2/TxA2 pathway Received : August 03, 2015 Accepted : October 09, 2015 Published : October 20, 2015 Abstract OBJECTIVES: This review stated the possible application of the active components of licorice, glycyrrhizin (GL) and glycyrrhetinic acid (GA), in rheumatoid arthritis (RA) treatment based on the cyclooxygenase (COX)-2/thromboxane A2 (TxA2) pathway. METHODS: The extensive literature from inception to July 2015 was searched in PubMed central, and relevant reports were identified according to the purpose of this study. RESULTS: The active components of licorice GL and GA exert the potential anti-inflammatory effects through, at least in part, suppressing COX-2 and its downstream product TxA2. Additionally, the COX-2/TxA2 pathway, an auto-regulatory feedback loop, has been recently found to be a crucial mechanism underlying the pathogenesis of RA. However, TxA2 is neither the pharmacological target of non-steroidal anti-inflammatory drugs (NSAIDs) nor the target of disease modifying anti-rheumatic drugs (DMARDs), and the limitations and side effects of those drugs may be, at least in part, attributable to lack of the effects on the COX-2/TxA2 pathway. Therefore, GL and GA capable of targeting this pathway hold the potential as a novel add-on therapy in therapeutic strategy, which is supported by several bench experiments. CONCLUSIONS: The active components of licorice, GL and GA, could not only potentiate the therapeutic effects but also decrease the adverse effects of NSAIDs or DMARDs through suppressing the COX-2/TxA2 pathway during treatment course of RA." @default.
• W1828400840 created "2016-06-24" @default.
• W1828400840 creator A5006915777 @default.
• W1828400840 creator A5026656604 @default.
• W1828400840 creator A5033580129 @default.
• W1828400840 creator A5059647302 @default.
• W1828400840 creator A5065967526 @default.
• W1828400840 creator A5072274385 @default.
• W1828400840 creator A5082079711 @default.
• W1828400840 date "2015-10-20" @default.
• W1828400840 modified "2023-09-29" @default.
• W1828400840 title "Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?" @default.
• W1828400840 cites W1805025665 @default.
• W1828400840 cites W1812897516 @default.
• W1828400840 cites W1831335230 @default.
• W1828400840 cites W1845493419 @default.
• W1828400840 cites W1846058897 @default.
• W1828400840 cites W1885723045 @default.
• W1828400840 cites W1964308104 @default.
• W1828400840 cites W1967558736 @default.
• W1828400840 cites W1970990257 @default.
• W1828400840 cites W1975829534 @default.
• W1828400840 cites W1982180396 @default.
• W1828400840 cites W1989203050 @default.
• W1828400840 cites W1993469532 @default.
• W1828400840 cites W2001676690 @default.
• W1828400840 cites W2003597161 @default.
• W1828400840 cites W2006228380 @default.
• W1828400840 cites W2006404223 @default.
• W1828400840 cites W2010619098 @default.
• W1828400840 cites W2011576049 @default.
• W1828400840 cites W2013162620 @default.
• W1828400840 cites W2013474471 @default.
• W1828400840 cites W2016950635 @default.
• W1828400840 cites W2017091837 @default.
• W1828400840 cites W2020258786 @default.
• W1828400840 cites W2021185028 @default.
• W1828400840 cites W2022205836 @default.
• W1828400840 cites W2022465723 @default.
• W1828400840 cites W2034594119 @default.
• W1828400840 cites W2037967805 @default.
• W1828400840 cites W2039138706 @default.
• W1828400840 cites W2039393993 @default.
• W1828400840 cites W2043522894 @default.
• W1828400840 cites W2047095661 @default.
• W1828400840 cites W2049967713 @default.
• W1828400840 cites W2055085159 @default.
• W1828400840 cites W2057262806 @default.
• W1828400840 cites W2058022688 @default.
• W1828400840 cites W2077232152 @default.
• W1828400840 cites W2081041695 @default.
• W1828400840 cites W2084735271 @default.
• W1828400840 cites W2087749458 @default.
• W1828400840 cites W2091384794 @default.
• W1828400840 cites W2092296830 @default.
• W1828400840 cites W2092801963 @default.
• W1828400840 cites W2095665485 @default.
• W1828400840 cites W2098416561 @default.
• W1828400840 cites W2099681552 @default.
• W1828400840 cites W2102691073 @default.
• W1828400840 cites W2109229905 @default.
• W1828400840 cites W2110320135 @default.
• W1828400840 cites W2115105286 @default.
• W1828400840 cites W2115250659 @default.
• W1828400840 cites W2126251812 @default.
• W1828400840 cites W2133611935 @default.
• W1828400840 cites W2142053769 @default.
• W1828400840 cites W2143522103 @default.
• W1828400840 cites W2156958131 @default.
• W1828400840 cites W2161493090 @default.
• W1828400840 cites W2163793937 @default.
• W1828400840 cites W2410905074 @default.
• W1828400840 cites W2418824387 @default.
• W1828400840 cites W252251803 @default.
• W1828400840 cites W30494026 @default.
• W1828400840 cites W333722535 @default.
• W1828400840 cites W2411304241 @default.
• W1828400840 doi "https://doi.org/10.18632/oncotarget.6200" @default.
• W1828400840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4811453" @default.
• W1828400840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26498361" @default.
• W1828400840 hasPublicationYear "2015" @default.
• W1828400840 type Work @default.
• W1828400840 sameAs 1828400840 @default.
• W1828400840 citedByCount "33" @default.
• W1828400840 countsByYear W18284008402017 @default.
• W1828400840 countsByYear W18284008402018 @default.
• W1828400840 countsByYear W18284008402019 @default.
• W1828400840 countsByYear W18284008402020 @default.
• W1828400840 countsByYear W18284008402021 @default.
• W1828400840 countsByYear W18284008402022 @default.
• W1828400840 countsByYear W18284008402023 @default.
• W1828400840 crossrefType "journal-article" @default.
• W1828400840 hasAuthorship W1828400840A5006915777 @default.
• W1828400840 hasAuthorship W1828400840A5026656604 @default.
• W1828400840 hasAuthorship W1828400840A5033580129 @default.
• W1828400840 hasAuthorship W1828400840A5059647302 @default.
• W1828400840 hasAuthorship W1828400840A5065967526 @default.
• W1828400840 hasAuthorship W1828400840A5072274385 @default.

• next